<DOC>
	<DOCNO>NCT02642965</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose liposomal cytarabine-daunorubicin CPX-351 ( CPX-351 ) give fludarabine phosphate , cytarabine , filgrastim see well work treat young patient acute myeloid leukemia come back treatment ( relapse ) respond treatment ( refractory ) . Liposomal cytarabine-daunorubicin CPX-351 make two chemotherapy drug , cytarabine daunorubicin hydrochloride , work stop cancer cell growth block cell divide . Drugs use chemotherapy , fludarabine phosphate cytarabine , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Filgrastim may increase production blood cell may help immune system recover side effect chemotherapy . Giving liposomal cytarabine-daunorubicin CPX-351 follow fludarabine phosphate , cytarabine , filgrastim may better treatment patient relapse acute myeloid leukemia may cause few side effect heart , common effect chemotherapy treatment acute myeloid leukemia .</brief_summary>
	<brief_title>Liposomal Cytarabine-Daunorubicin CPX-351 , Fludarabine Phosphate , Cytarabine , Filgrastim Treating Younger Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine recommended phase 2 dose ( RP2D ) toxicity associate CPX-351 pediatric young adult patient relapsed/refractory acute myeloid leukemia ( AML ) . II . To estimate response rate ( complete remission [ CR ] plus complete remission partial platelet recovery [ CRp ] ) CPX-351 ( cycle 1 ) follow fludarabine phosphate , cytarabine , filgrastim ( FLAG ) ( cycle 2 ) child AML first relapse . SECONDARY OBJECTIVES : I . To estimate response rate ( CR + CRp + complete remission incomplete blood count recovery [ CRi ] ) one cycle CPX-351 . II . To describe pharmacokinetics plasma cytarabine daunorubicin CPX-351 administration pediatric young adult patient relapsed/refractory AML . TERTIARY OBJECTIVES : I . To describe response biomarkers cardiac injury single cycle CPX-351 . II . To explore effect CPX-351 novel biochemical imaging marker cardiotoxicity , include plasma micro ribonucleic acid ( RNAs ) ( miRNA ) myocardial deformation . III . To explore role rare cod variant risk factor anthracycline-induced cardiomyopathy . OUTLINE : COURSE 1 : Patients receive cytarabine intrathecally ( IT ) day 0 day 28-30 1 week prior day 1 course 2 , liposomal cytarabine-daunorubicin CPX-351 intravenously ( IV ) 90 minute day 1 , 3 , 5 . Patients without evidence central nervous system ( CNS ) disease ( CNS1 ) receive CNS-directed therapy course 1 . Patients &lt; 5 white blood cell per microliter blood blast cell ( CNS2 ) disease may receive additional dose cytarabine IT day 7 discretion investigator . Patients meet criterion CR , CRp , CRi may proceed course 2 . COURSE 2 : Beginning 28 day later , patient receive filgrastim subcutaneously ( SC ) day 1-5 day 15 blood count recovery , fludarabine phosphate IV 30 minute high-dose cytarabine IV 1-3 hour day 1-5 . After completion study treatment , patient follow periodically 12 month , yearly 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients must histologic verification AML original diagnosis ; AML define accord World Health Organization ( WHO ) classification &gt; = 5 % blast bone marrow ( M2/M3 bone marrow ) , without extramedullary disease To eligible dosefinding phase : Relapsed patient Patients must first relapse , Patients must receive prior reinduction therapy Refractory patient Patients must receive one attempt remission induction , may consist two different therapy course ; Children Oncology Group ( COG ) AAML1031 de novo therapy include induction I induction II example Treatmentrelated AML ( tAML ) Patients must previously untreated secondary AML To eligible efficacy phase : Relapsed patient : Patients must first relapse , Patients must receive prior reinduction therapy Patients must status CNS1 CNS2 , clinical sign neurologic symptom suggestive CNS leukemia , cranial palsy Patients must performance status correspond Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 2 ; use Karnofsky patient &gt; 16 year age Lansky patient = &lt; 16 year age ; Note : patient unable walk paralysis , wheelchair , consider ambulatory purpose assess performance score Patients must recover acute toxic effect prior chemotherapy , immunotherapy , stem cell transplant radiotherapy prior enter study ; prior treatmentrelated toxicity must resolve = &lt; grade 2 prior enrollment Myelosuppressive chemotherapy : must receive myelosuppressive chemotherapy within 3 week entry onto study ( exclude hydroxyurea ) Cytoreduction hydroxyurea initiate continue 24 hour prior start CPX351 Biologic ( antineoplastic agent ) : least 7 day since completion therapy biologic agent steroid , retinoids , DLI ( donor lymphocyte infusion without condition ) ; Note : agent know adverse event occur beyond 7 day administration ( i.e . monoclonal antibody ) , period must extend beyond time acute adverse event know occur Radiation therapy ( RT ) : &gt; = 2 week local palliative RT ( small port ) ; &gt; = 6 month must elapse prior craniospinal RT &gt; = 50 % radiation pelvis ; &gt; = 6 week must elapse substantial bone marrow ( BM ) radiation ; Note : patient must receive = &lt; 13.6 Gray ( Gy ) prior radiation mediastinum Stem cell transplant ( SCT ) : evidence active graft vs. host disease least 4 week ; allogeneic SCT patient , &gt; = 3 month must elapse since transplant Must receive 1 prior autologous allogeneic stem cell transplant . Patients must systemic immunosuppressive therapy least 2 week , exclude hydrocortisone physiologic cortisol replacement Intrathecal cytotoxic therapy : No wait period require patient receive intrathecal cytarabine , methotrexate , and/or hydrocortisone At least 14 day must elapse since receive liposomal cytarabine ( DepoCyte ) intrathecal injection Growth factor : Patients must receive growth factor 7 day prior CPX351 Patients must receive pegfilgrastim 14 day prior CPX351 Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 serum creatinine base age/gender follow : Age 1 &lt; 2 year : maximum serum creatinine 0.6 mg/dL ( male female ) Age 2 &lt; 6 year : maximum serum creatinine 0.8 mg/dL ( male female ) Age 6 &lt; 10 year : maximum serum creatinine 1.0 mg/dL ( male female ) Age 10 &lt; 13 year : maximum serum creatinine 1.2 mg/dL ( male female ) Age 13 &lt; 16 year : maximum serum creatinine 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) Age &gt; = 16 year : maximum serum creatinine 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) Direct bilirubin &lt; 1.5 x upper limit normal ( ULN ) age institution Serum glutamate pyruvate ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; 3.0 x upper limit normal ( ULN ) age institution ( unless relate leukemic involvement ) Shortening fraction &gt; = 27 % echocardiogram , Ejection fraction &gt; = 50 % radionuclide angiogram echocardiogram Corrected QT ( use Bazett 's formula [ QTcB ] ) interval &lt; 500 msec Patients seizure disorder may enrol anticonvulsant seizures well controlled Central nervous system ( CNS ) toxicity = &lt; grade 2 Patients known history human immunodeficiency virus ( HIV ) eligible , meet following condition : No history HIV complication exception cluster differentiation ( CD ) 4 count &lt; 200 cells/mm^3 No antiretroviral therapy overlap toxicity myelosuppression HIV viral load limit detection No history highly active antiretroviral therapy ( HAART ) resistant HIV All patient and/or parent legal guardian must sign write informed consent Patients receive &gt; 450 mg/m^2 daunorubicin equivalent ; patient relapse receive AAML0531/AAML1031 therapy eligible study , provide receive additional anthracyclines ; NOTE : purpose determine eligibility protocol , follow cardiotoxicity multiplier use determine daunorubicin equivalent : Doxorubicin ( doxorubicin hydrochloride ) : 1 Mitoxantrone : 3 Idarubicin : 3 Epirubicin : 0.5 Patients currently receive another investigational drug Patients receive medication treatment leave ventricular systolic dysfunction Patients follow diagnosis : Acute promyelocytic leukemia ( APL ) Down syndrome Fanconi anemia , Kostmann syndrome , Shwachman syndrome know bone marrow failure syndrome Wilson 's disease disorder copper metabolism Juvenile myelomonocytic leukemia ( JMML ) Patients document active , uncontrolled infection time study entry Patients know active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection Patients prior allergy daunorubicin , cytarabine allergy liposomal lipid Female patient pregnant ineligible Lactating female eligible Female patient childbearing potential eligible unless negative pregnancy test result obtain Sexually active patient reproductive potential eligible unless agree use effective contraceptive method duration study participation 30 day last dose chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>